These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 15820075)

  • 21. Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences.
    Boisdron-Celle M; Craipeau C; Brienza S; Delva R; Guérin-Meyer V; Cvitkovic E; Gamelin E
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):235-43. PubMed ID: 11935216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer.
    Saeki H; Ito S; Futatsugi M; Kimura Y; Ohga T; Sugimachi K
    Anticancer Res; 2002; 22(6B):3789-92. PubMed ID: 12552994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
    ; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
    J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
    Okumura K; Mekata E; Shiomi H; Naitoh H; Abe H; Endo Y; Kurumi Y; Tani T
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):587-94. PubMed ID: 17520254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential methotrexate plus 5-FU in advanced breast and colorectal cancers: a phase II study.
    Kaye SB; Sangster G; Hutcheon A; Habeshaw T; Crossling F; Ferguson C; McArdle C; Smith D; George WD; Calman KC
    Cancer Treat Rep; 1984 Mar; 68(3):547-8. PubMed ID: 6704984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Expression of dihydropyrimidine dehydrogenase in human colorectal carcinoma and its clinical implications].
    Xiao JX; Han M; Li L; Zhu J; Chen LH; Bai PS
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2136-9. PubMed ID: 16313827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer.
    Del Freo A; Fiorentini G; Sanguinetti F; Muttini MP; Pennucci C; Mambrini A; Pacetti P; Della Seta R; Lombardi M; Torri T; Cantore M
    In Vivo; 2006; 20(6A):743-6. PubMed ID: 17203759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression of dihydropyrimidine dehydrogenase in primary colorectal cancer and liver metastasis--a relationship between mRNA levels in cancer cells and protein levels in cancerous tissue and effect of 5-fluorouracil].
    Ishibashi K; Sobajima J; Ishiguro T; Ohsawa T; Okada N; Miyazaki T; Yokoyama M; Inokuma S; Ishida H
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2232-5. PubMed ID: 20037380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls.
    Raida M; Kliche KO; Schwabe W; Häusler P; Clement JH; Behnke D; Höffken K
    J Cancer Res Clin Oncol; 2002 Feb; 128(2):96-102. PubMed ID: 11862480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.
    Ashley AC; Sargent DJ; Alberts SR; Grothey A; Campbell ME; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Goldberg RM
    Cancer; 2007 Aug; 110(3):670-7. PubMed ID: 17559146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients.
    Furuhata T; Kawakami M; Okita K; Kimura Y; Kihara C; Tsuruma T; Ohmura T; Yamaguchi K; Hata F; Katsuramaki T; Sasaki K; Hirata K
    J Exp Clin Cancer Res; 2006 Mar; 25(1):79-82. PubMed ID: 16761622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlations of clinicopathological factors with protein expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in colorectal cancer.
    Sumi T; Katsumata K; Tsuchida A; Ishizaki T; Shimazu M; Aoki T
    Chemotherapy; 2010; 56(2):120-6. PubMed ID: 20407238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
    Tokunaga Y; Sasaki H; Saito T
    Surgery; 2007 Mar; 141(3):346-53. PubMed ID: 17349846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
    Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
    J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hepatic recurrence after prophylactic hepatic arterial infusion of 5-fluorouracil for Dukes' C colorectal cancer--correlation with the expression of dihydropyrimidine dehydrogenase in the primary tumor].
    Ishida H; Takeuchi I; Ohsawa T; Nakada H; Ishizuka N; Yokoyama M; Inokuma S; Suzuki T; Yamada H; Odaka A; Hoshino T; Murata N; Hashimoto D; Matsumoto Y; Miura T
    Gan To Kagaku Ryoho; 2002 Nov; 29(12):2267-70. PubMed ID: 12484051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
    Wettergren Y; Carlsson G; Odin E; Gustavsson B
    Cancer; 2012 Jun; 118(11):2935-43. PubMed ID: 22020693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer].
    Chiba N; Yoshioka T; Kato S; Takahashi S; Shibata H; Kato S; Sakayori M; Otsuka K; Kakudo Y; Ohori H; Yamaura G; Takahashi M; Yasuda K; Ishioka C
    Gan To Kagaku Ryoho; 2005 Jul; 32(7):991-5. PubMed ID: 16044961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
    Cho BC; Kim JH; Kim CB; Sohn JH; Choi HJ; Lee YC; Ahn JB
    Oncol Rep; 2006 Mar; 15(3):621-7. PubMed ID: 16465422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
    Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.